Surgical Research Laboratory, Department of Surgery, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Section of Hepatology and Hume-Lee Transplant Center, Virginia Commonwealth University, Richmond, VA.
Hepatology. 2021 May;73(5):1882-1891. doi: 10.1002/hep.31507.
Recent studies of acute liver failure (ALF) in man and animals have suggested that rebalanced hemostasis occurs, with distinct hypercoagulable features clinically evidenced by a low risk of bleeding. Rodent models have shown a link between intrahepatic microthrombus formation and progression of ALF. We sought to confirm these earlier findings in a large series of patients with well-characterized ALF from the Acute Liver Failure Study Group.
Citrated plasma samples taken on admission from 676 patients with ALF or acute liver injury (international normalized ratio ≥2.0 without hepatic encephalopathy) were used to determine levels of von Willebrand factor (VWF), a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) activity, thrombomodulin-modified thrombin generation, and clot lysis time (CLT) and compared with the levels in 40 healthy controls. Patients had 3-fold increased VWF levels, 4-fold decreased ADAMTS13 activity, similar thrombin generating capacity, and 2.4-fold increased CLT, compared with controls. Increasing disease severity was associated with progressively more elevated VWF levels as well as hypofibrinolysis. Patients who died or underwent liver transplantation within 21 days of admission had higher VWF levels, lower ADAMTS13 activity, but similar thrombin generation and a similar proportion of patients with severe hypofibrinolysis, when compared with transplant-free survivors. Likewise, patients with bleeding complications had higher VWF levels and lower ADAMTS13 activity compared to those without bleeding. Thrombin generation and CLT did not differ significantly between bleeding and nonbleeding patients.
Rebalanced hemostatic status was confirmed in a large cohort of patients with acute liver injury/ALF, demonstrating that VWF/ADAMTS13 imbalance is associated with poor outcome and bleeding. The association between VWF/ADAMTS13 imbalance and bleeding suggests that bleeding in ALF relates more to systemic inflammation than a primary coagulopathy.
最近对人类和动物的急性肝衰竭(ALF)的研究表明,止血平衡得到恢复,临床上表现出明显的高凝状态,出血风险低。啮齿动物模型表明肝内微血栓形成与 ALF 的进展之间存在关联。我们试图在急性肝衰竭研究组的一大组具有明确 ALF 的患者中证实这些早期发现。
从 676 名 ALF 或急性肝损伤患者(国际标准化比值≥2.0 且无肝性脑病)入院时采集枸橼酸盐血浆样本,用于测定血管性血友病因子(VWF)、去整合素和金属蛋白酶与血小板反应素 1 型基序 13(ADAMTS13)活性、血栓调节素修饰的凝血酶生成和纤维蛋白溶解时间(CLT)水平,并与 40 名健康对照者进行比较。与对照组相比,患者的 VWF 水平增加了 3 倍,ADAMTS13 活性降低了 4 倍,凝血酶生成能力相似,CLT 增加了 2.4 倍。随着疾病严重程度的增加,VWF 水平逐渐升高,纤溶作用降低。与存活至 21 天的患者相比,入院后 21 天内死亡或接受肝移植的患者 VWF 水平更高,ADAMTS13 活性更低,但凝血酶生成相似,且严重纤溶减少的患者比例相似。同样,与无出血并发症的患者相比,有出血并发症的患者 VWF 水平更高,ADAMTS13 活性更低。出血和非出血患者的凝血酶生成和 CLT 无显著差异。
在一大组急性肝损伤/ALF 患者中证实了止血平衡的恢复,表明 VWF/ADAMTS13 失衡与不良预后和出血相关。VWF/ADAMTS13 失衡与出血之间的关联表明,ALF 中的出血与全身性炎症的关系更密切,而不是原发性凝血功能障碍。